 Taizo Nakano
Concepts (187)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Aplastic | 11 | 2026 | 42 | 2.500 |
Why?
| | Purpura, Thrombocytopenic, Idiopathic | 4 | 2026 | 18 | 1.530 |
Why?
| | Myelodysplastic Syndromes | 3 | 2021 | 165 | 1.260 |
Why?
| | Bone Marrow Diseases | 3 | 2023 | 20 | 0.990 |
Why?
| | Kasabach-Merritt Syndrome | 2 | 2023 | 8 | 0.920 |
Why?
| | Hematologic Diseases | 2 | 2023 | 66 | 0.920 |
Why?
| | Pancytopenia | 1 | 2023 | 7 | 0.770 |
Why?
| | Chylous Ascites | 1 | 2022 | 5 | 0.740 |
Why?
| | Chylothorax | 1 | 2022 | 20 | 0.730 |
Why?
| | Noonan Syndrome | 1 | 2022 | 14 | 0.720 |
Why?
| | Respiration Disorders | 1 | 2022 | 78 | 0.700 |
Why?
| | Leukemia, Myeloid, Acute | 3 | 2022 | 688 | 0.630 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 3 | 2026 | 29 | 0.580 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2024 | 699 | 0.540 |
Why?
| | Child | 27 | 2026 | 22740 | 0.490 |
Why?
| | Practice Patterns, Physicians' | 2 | 2026 | 1372 | 0.460 |
Why?
| | Benzoates | 2 | 2025 | 51 | 0.450 |
Why?
| | Hydrazines | 2 | 2025 | 37 | 0.450 |
Why?
| | Decision Making | 1 | 2020 | 982 | 0.370 |
Why?
| | Lymphatic Abnormalities | 2 | 2025 | 20 | 0.370 |
Why?
| | Sialic Acids | 1 | 2011 | 8 | 0.350 |
Why?
| | Pyrazoles | 2 | 2025 | 517 | 0.340 |
Why?
| | Antineoplastic Agents | 1 | 2022 | 2219 | 0.320 |
Why?
| | Immunosuppressive Agents | 3 | 2025 | 838 | 0.300 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2026 | 992 | 0.290 |
Why?
| | Child, Preschool | 17 | 2026 | 11868 | 0.280 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2012 | 297 | 0.280 |
Why?
| | Humans | 38 | 2026 | 145783 | 0.280 |
Why?
| | Antibodies, Monoclonal | 2 | 2026 | 1505 | 0.270 |
Why?
| | MDS1 and EVI1 Complex Locus Protein | 2 | 2023 | 8 | 0.240 |
Why?
| | Receptors, Thrombopoietin | 1 | 2025 | 6 | 0.230 |
Why?
| | Polyarteritis Nodosa | 1 | 2025 | 11 | 0.230 |
Why?
| | Severe Combined Immunodeficiency | 1 | 2025 | 22 | 0.230 |
Why?
| | Adenosine Deaminase | 1 | 2025 | 43 | 0.230 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2011 | 1450 | 0.220 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 2 | 2023 | 126 | 0.220 |
Why?
| | Antibodies, Antiphospholipid | 1 | 2024 | 29 | 0.210 |
Why?
| | Infant | 13 | 2026 | 10091 | 0.210 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2025 | 376 | 0.200 |
Why?
| | Arthritis, Juvenile | 1 | 2024 | 60 | 0.200 |
Why?
| | Hemangioendothelioma | 1 | 2023 | 13 | 0.200 |
Why?
| | Disease Management | 2 | 2026 | 653 | 0.200 |
Why?
| | Vascular Neoplasms | 1 | 2023 | 19 | 0.200 |
Why?
| | Hemangioma | 1 | 2023 | 46 | 0.200 |
Why?
| | Rheumatic Diseases | 1 | 2024 | 98 | 0.200 |
Why?
| | Adolescent | 15 | 2026 | 22577 | 0.190 |
Why?
| | Neoplasms | 2 | 2026 | 2913 | 0.190 |
Why?
| | Sarcoma, Kaposi | 1 | 2023 | 83 | 0.190 |
Why?
| | Proto-Oncogenes | 1 | 2022 | 28 | 0.190 |
Why?
| | Cyclosporine | 2 | 2025 | 256 | 0.180 |
Why?
| | Fanconi Anemia | 1 | 2022 | 11 | 0.180 |
Why?
| | Wnt Signaling Pathway | 1 | 2024 | 212 | 0.180 |
Why?
| | Venous Thrombosis | 1 | 2024 | 196 | 0.180 |
Why?
| | Terminology as Topic | 1 | 2024 | 259 | 0.180 |
Why?
| | Ascites | 1 | 2022 | 48 | 0.180 |
Why?
| | Syndrome | 1 | 2023 | 381 | 0.180 |
Why?
| | Exocrine Pancreatic Insufficiency | 1 | 2022 | 24 | 0.180 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2023 | 254 | 0.180 |
Why?
| | Guideline Adherence | 1 | 2026 | 587 | 0.170 |
Why?
| | Pyrimidinones | 1 | 2022 | 125 | 0.170 |
Why?
| | Drainage | 1 | 2022 | 185 | 0.170 |
Why?
| | Genetic Counseling | 1 | 2021 | 80 | 0.170 |
Why?
| | Bone Marrow Transplantation | 2 | 2020 | 298 | 0.160 |
Why?
| | Hepatitis | 1 | 2021 | 43 | 0.160 |
Why?
| | Retrospective Studies | 10 | 2026 | 17330 | 0.160 |
Why?
| | Pyridones | 1 | 2022 | 209 | 0.160 |
Why?
| | Young Adult | 10 | 2026 | 14254 | 0.150 |
Why?
| | Prognosis | 4 | 2020 | 4330 | 0.150 |
Why?
| | Antilymphocyte Serum | 1 | 2019 | 57 | 0.150 |
Why?
| | Hematopoietic System | 1 | 2018 | 7 | 0.140 |
Why?
| | Communication | 1 | 2025 | 977 | 0.140 |
Why?
| | Treatment Outcome | 8 | 2026 | 11794 | 0.140 |
Why?
| | Sclerotherapy | 1 | 2018 | 19 | 0.140 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 2018 | 36 | 0.140 |
Why?
| | Survival Rate | 2 | 2020 | 2094 | 0.140 |
Why?
| | Metformin | 1 | 2022 | 329 | 0.140 |
Why?
| | Zebrafish | 1 | 2023 | 532 | 0.140 |
Why?
| | Doxycycline | 1 | 2018 | 62 | 0.140 |
Why?
| | Female | 19 | 2026 | 79045 | 0.130 |
Why?
| | Time-to-Treatment | 1 | 2020 | 251 | 0.130 |
Why?
| | Transcription Factors | 2 | 2023 | 1736 | 0.130 |
Why?
| | Male | 19 | 2026 | 73011 | 0.130 |
Why?
| | Genome-Wide Association Study | 1 | 2024 | 1430 | 0.130 |
Why?
| | Electronic Health Records | 1 | 2025 | 1202 | 0.130 |
Why?
| | Liver Transplantation | 1 | 2024 | 827 | 0.120 |
Why?
| | Secondary Prevention | 1 | 2018 | 251 | 0.120 |
Why?
| | Parents | 1 | 2025 | 1407 | 0.120 |
Why?
| | Spleen | 1 | 2018 | 508 | 0.120 |
Why?
| | Skin Neoplasms | 1 | 2023 | 853 | 0.120 |
Why?
| | Adult | 12 | 2026 | 40881 | 0.120 |
Why?
| | Patient Selection | 1 | 2020 | 739 | 0.120 |
Why?
| | Surveys and Questionnaires | 3 | 2026 | 6085 | 0.110 |
Why?
| | Immunoglobulins, Intravenous | 2 | 2026 | 133 | 0.110 |
Why?
| | Phenotype | 1 | 2023 | 3170 | 0.110 |
Why?
| | North America | 2 | 2026 | 304 | 0.100 |
Why?
| | Antibodies, Neutralizing | 2 | 2026 | 340 | 0.090 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2016 | 673 | 0.090 |
Why?
| | Hyperbilirubinemia | 1 | 2012 | 11 | 0.090 |
Why?
| | Sialyltransferases | 1 | 2011 | 13 | 0.090 |
Why?
| | Induction Chemotherapy | 1 | 2012 | 88 | 0.090 |
Why?
| | Anemia, Hemolytic, Congenital | 1 | 2011 | 1 | 0.080 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 95 | 0.080 |
Why?
| | Porphyria, Erythropoietic | 1 | 2011 | 2 | 0.080 |
Why?
| | Organ Specificity | 1 | 2011 | 309 | 0.080 |
Why?
| | Pancreatitis | 1 | 2012 | 146 | 0.080 |
Why?
| | Interdisciplinary Communication | 1 | 2012 | 201 | 0.080 |
Why?
| | HLA Antigens | 2 | 2022 | 240 | 0.080 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2012 | 138 | 0.080 |
Why?
| | Inflammation | 1 | 2022 | 2884 | 0.080 |
Why?
| | Evidence-Based Medicine | 2 | 2024 | 740 | 0.080 |
Why?
| | Liver | 1 | 2018 | 1899 | 0.080 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1969 | 0.080 |
Why?
| | Follow-Up Studies | 4 | 2020 | 5428 | 0.080 |
Why?
| | Neoplasm Proteins | 1 | 2011 | 442 | 0.070 |
Why?
| | Recurrence | 2 | 2024 | 1139 | 0.070 |
Why?
| | Severity of Illness Index | 3 | 2025 | 2933 | 0.070 |
Why?
| | Hyperglycemia | 1 | 2012 | 380 | 0.070 |
Why?
| | T-Lymphocytes | 1 | 2016 | 1998 | 0.070 |
Why?
| | Pilot Projects | 2 | 2025 | 1898 | 0.060 |
Why?
| | Practice Guidelines as Topic | 2 | 2026 | 1582 | 0.060 |
Why?
| | Combined Modality Therapy | 2 | 2020 | 1271 | 0.060 |
Why?
| | Patient Care Team | 1 | 2012 | 697 | 0.060 |
Why?
| | Rho(D) Immune Globulin | 1 | 2025 | 6 | 0.060 |
Why?
| | Agammaglobulinemia | 1 | 2025 | 36 | 0.060 |
Why?
| | Platelet Count | 1 | 2025 | 94 | 0.060 |
Why?
| | Still's Disease, Adult-Onset | 1 | 2024 | 5 | 0.050 |
Why?
| | Antiphospholipid Syndrome | 1 | 2024 | 37 | 0.050 |
Why?
| | Mutation, Missense | 1 | 2025 | 335 | 0.050 |
Why?
| | Middle Aged | 5 | 2025 | 36309 | 0.050 |
Why?
| | Breast Neoplasms | 1 | 2016 | 2393 | 0.050 |
Why?
| | Vincristine | 1 | 2023 | 144 | 0.050 |
Why?
| | Administration, Oral | 1 | 2025 | 867 | 0.050 |
Why?
| | Infant, Newborn | 3 | 2019 | 6465 | 0.050 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2022 | 43 | 0.050 |
Why?
| | HLA-B Antigens | 1 | 2022 | 58 | 0.050 |
Why?
| | Chromosome Inversion | 1 | 2022 | 20 | 0.050 |
Why?
| | Animals | 4 | 2023 | 38102 | 0.050 |
Why?
| | Drug Therapy, Combination | 1 | 2025 | 1043 | 0.050 |
Why?
| | Prospective Studies | 2 | 2025 | 8078 | 0.040 |
Why?
| | Sirolimus | 1 | 2023 | 282 | 0.040 |
Why?
| | Fetal Hemoglobin | 1 | 2021 | 8 | 0.040 |
Why?
| | United States | 3 | 2026 | 16126 | 0.040 |
Why?
| | Glucocorticoids | 1 | 2025 | 532 | 0.040 |
Why?
| | Eukaryotic Initiation Factors | 1 | 2021 | 12 | 0.040 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2022 | 202 | 0.040 |
Why?
| | Liver Diseases | 1 | 2024 | 305 | 0.040 |
Why?
| | Telomere | 1 | 2024 | 287 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2025 | 2000 | 0.040 |
Why?
| | Unrelated Donors | 1 | 2020 | 39 | 0.040 |
Why?
| | Venous Thromboembolism | 1 | 2024 | 328 | 0.040 |
Why?
| | Hemorrhage | 1 | 2025 | 822 | 0.040 |
Why?
| | Mice | 2 | 2022 | 18356 | 0.040 |
Why?
| | Bone Marrow | 1 | 2021 | 307 | 0.040 |
Why?
| | Zebrafish Proteins | 1 | 2023 | 314 | 0.040 |
Why?
| | Tacrolimus | 1 | 2021 | 196 | 0.040 |
Why?
| | Horses | 1 | 2021 | 226 | 0.040 |
Why?
| | Genotype | 1 | 2024 | 1857 | 0.040 |
Why?
| | Alleles | 1 | 2022 | 896 | 0.040 |
Why?
| | Genetic Variation | 1 | 2024 | 977 | 0.040 |
Why?
| | Ribosomes | 1 | 2021 | 193 | 0.040 |
Why?
| | Anticoagulants | 1 | 2024 | 748 | 0.040 |
Why?
| | Abdominal Cavity | 1 | 2018 | 5 | 0.040 |
Why?
| | Phosphorylation | 1 | 2023 | 1708 | 0.040 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 1 | 2018 | 19 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2021 | 1512 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2024 | 2181 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2021 | 534 | 0.030 |
Why?
| | Ultrasonography, Interventional | 1 | 2018 | 166 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2023 | 878 | 0.030 |
Why?
| | Emulsions | 1 | 2016 | 59 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2024 | 2399 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2020 | 1115 | 0.030 |
Why?
| | Mutation | 2 | 2021 | 4090 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2022 | 1482 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2016 | 1043 | 0.020 |
Why?
| | Quality of Life | 1 | 2025 | 3211 | 0.020 |
Why?
| | Base Sequence | 1 | 2016 | 2171 | 0.020 |
Why?
| | Uroporphyrinogen III Synthetase | 1 | 2011 | 1 | 0.020 |
Why?
| | Photosensitivity Disorders | 1 | 2011 | 8 | 0.020 |
Why?
| | Cohort Studies | 1 | 2022 | 6033 | 0.020 |
Why?
| | Cell Line | 1 | 2016 | 2823 | 0.020 |
Why?
| | Colorado | 1 | 2021 | 4556 | 0.020 |
Why?
| | Homozygote | 1 | 2011 | 199 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2011 | 305 | 0.020 |
Why?
| | Lung Injury | 1 | 2011 | 249 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3916 | 0.010 |
Why?
| | Hypertension, Pulmonary | 1 | 2011 | 1957 | 0.010 |
Why?
|
|
Nakano's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|